Corbus updates risk factors; no new operational or financial events

Corbus Pharmaceuticals Holdings, Inc.

Filing supplements risk factors for Q1 2024; no change in business outlook.
Highlights dependence on contract manufacturers and CROs for clinical supply.
Notes exposure to U.S.-China trade policies and proposed BIOSECURE bill through CSPC license.
Repeats standard IP infringement litigation risks; no suits filed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.